Recent publication in the International Journal of Impotence Research Highlights Xialla's potential

Last updated: August 26, 2023

Groundbreaking Xialla® Device Addresses Erectile Dysfunction Due to Veno-Occlusive Dysfunction

Recent publication in the International Journal of Impotence Research highlights Xialla's potential

[OTTAWA, AUG 26, 2023] – A revolutionary advancement in the treatment of erectile dysfunction (ED) due to veno-occlusive dysfunction (VOD) has been highlighted in the form of Xialla®, a novel constriction ring. The details of this breakthrough were recently published in the International Journal of Impotence Research, the world's leading publication for erectile dysfunction related research and development.

A link to the full publication is here: https://www.nature.com/articles/s41443-023-00754-w.

Venous leak or VOD is a factor in 75% of ED cases. Traditional treatments for this condition have often been challenging, leaving patients seeking effective alternatives. Xialla® emerges as a scientifically validated FDA class II wearable device, uniquely designed to tackle ED related to venous leak.

Dr. Anthony J. Bella's clinical trial presented at the World Meeting on Sexual Medicine 2016 showcased the Xialla® device's remarkable capability. The trial revealed a significant enhancement in erectile function in 66% of the participants using the device. Further studies reinforced these results, underscoring Xialla®'s potential efficacy.

Distinctive features of Xialla®:

Versatile Design: The device can be applied whether the penis is erect or flaccid.
Enhanced Comfort: Unlike traditional rings that require a tight fit, Xialla®'s design ensures maximum comfort.
Functional & Discreet: Made of a soft silicone material, the device provides functionality without sacrificing discretion.

Additionally, Xialla®'s design addresses blood leakage during intercourse, potentially elevating its therapeutic efficiency over conventional rings. The device's multifunctionality extends to its simultaneous use with other ED therapies, offering comprehensive solutions for ED management.

Xialla® has also been tested as a potential treatment for climacturia, an involuntary loss of urine during sexual activity after prostate cancer surgery. In a trial involving patients who were unresponsive to other treatments for climacturia, impressive outcomes were observed. Notably, four out of five participants reported no urine leakage during sexual activity once the Xialla device was in use.

However, as with any medical device, caution is advised. Extended wear or forgetting to remove the device can result in severe clinical consequences due to penile constriction. Immediate removal is essential to restore blood flow and prevent tissue damage.

Future multicenter trials are planned to solidify Xialla®'s standing in the medical community. The device represents a promising shift in ED treatment – moving beyond merely managing symptoms to potentially restoring erections to a pre-pathological state.

For more information on Xialla® and the full findings of the study, please visit Xialla's website.

About the Authors:

The research was conducted by Faysal A. Yafi & Muhammed A. M. Hammad from the Department of Urology, University of California, and Dean Elterman from the Division of Urology, Department of Surgery, University of Toronto.